A phase IV clinical trial of Licartin combined with TACE for prevention of hepatocellular carcinoma recurrence

INTERVENTION: B:Conventional TACE;A:Licartin with conventional TACE; CONDITION: Hepatocellular carcinoma PRIMARY OUTCOME: Time to tumor progression (TTP);3, 6, 12, 24‐month recurrence rate; SECONDARY OUTCOME: safety of Licartin for hepatocelluar carcinoma;1, 2, 3, 5‐year survival rate;overall survival, OS; INCLUSION CRITERIA: 1. Patients are entirely voluntary, good compliance, sign the informed consent form, Age 18 to 80 years; 2. Diagnosis of hepatocellular carcinoma by pathology or clinical diagnosis; 3. Barcelona Clinic Liver Cancer (BCLC) classification: stage B or C; 4. ECOG score of physical state <=2 points; 5. Liver function is Child‐Pugh A or B class; 6. Leucocyte counts >=3*10^9/L, platelet counts >70*10^9/L; 7. No organ severe dysfunction; 8. Expected survival >=3 months.